AroCell: Funding secured, next step – FDA

Research Update



We adjust our financial projections given a new view on pricing and market uptake for AroCell. In our update we slightly raise our Base Case to SEK 2.5 per share and discuss the capital raise, which we believe will fund operations until FDA approval in 2021.


Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.